Home › NDC Lookup › Ingredients › Dimethyl Sulfoxide › 67457-0177-50
RIMSO-50 Dimethyl Sulfoxide .54 g/mL Irrigant — NDC 67457-0177-50 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

RIMSO-50 Dimethyl Sulfoxide .54 g/mL Irrigant — NDC 67457-177-50 (Billing 67457-0177-50)

by Mylan Institutional LLC · 1 VIAL, GLASS in 1 CARTON / 50 mL in 1 VIAL, GLASS

This is a package of RIMSO-50 Dimethyl Sulfoxide .54 g/mL Irrigant from Mylan Institutional LLC, marketed since Apr 1978 and currently FDA-listed. It is this product's only package size.

NDC 67457-0177-50
🏷️ FDA NDC (as labeled) 67457-177-50 billing pads the product segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 67457-177-50 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
67457 labeler · 177 product · 50 package
Package marketed since
Apr 4, 1978
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 6745717750 2
Medicaid fills, this package
578 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 67457-177-50
Product NDC 67457-177
11-digit billing NDC 67457017750
NCPDP billing unit ML — per mL (volume)
RxCUI 208361, 562359
UNII YOW8V9698H
Application # NDA017788
SPL Set ID 58b25d79-78f2-4953-b0c6-61658dc4ef0d
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1978-04-04
Route INTRAVESICAL
Dosage form IRRIGANT
Substance DIMETHYL SULFOXIDE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 56500010002010
GPI class Rimso-50
GCN Seq No 064336
GCN 13356
HICL code 004125
Ingredient (HICL) Dimethyl Sulfoxide
HIC1 code R
Therapeutic class — broad (HIC1) Kidney/Urinary Tract
HIC2 code R5
Therapeutic class — intermediate (HIC2) Urinary Tract Anesthetic/Analgesic Agents
HIC3 code R5B
Therapeutic class — specific (HIC3) Urinary Tract Analgesic Agents
AHFS code 40:36.00.00
AHFS class Irrigating Solutions
FDB label name RIMSO-50 SOLUTION
FDB brand name Rimso-50
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 064336
  • GCN: 13356
  • GPI-14 (Medi-Span): 56500010002010
  • HICL (First Databank): 004125
  • AHFS class code: 40:36.00.00
  • RxCUI (RxNorm): 208361
Why two NDCs? The FDA registers this code as 67457-177-50 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 67457-0177-50. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Other urologicals class.

Drug family (ATC) Other urologicals, Other topical products for joint and muscular pain
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name RIMSO-50 SOLUTION Ingredient Dimethyl Sulfoxide

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $10.69 $10.69 / 1 vial
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J1212 $748.879 / J1212 unit —
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)67457-177-50
11-digit billing NDC67457-0177-50
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ1212
DescriptorINJECTION, DMSO, DIMETHYL SULFOXIDE, 50%, 50 ML
Billing units / pkg0.02 units
How the units are derivedThis package is 50 ML; the HCPCS unit is 50 %, so one package = 0.02 billing units.
Medicare Part B spend (2026 (Q1))$909,558 · 1,256 claims · $724.17 per claim (all NDCs under J1212)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
67457-0177-50 You're viewing this Main listing 1 VIAL, GLASS in 1 CARTON / 50 mL in 1 VIAL, GLASS 1978-04-04 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Rimso-50 .54 g/mLthis 67457-0177-50 Mylan 1 vial — AT FDA listed —
Dimethyl Sulfoxide .54 g/mL 84897-0052-01 Renova 1 vial — AT FDA listed —
About this product: this is the brand-name version. Some generic versions are approved by the FDA, but we could not confirm current pharmacy availability from our pricing/market data.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1978
On the market since
Apr 1978
📍
2026
Currently FDA-listed
48 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

1 inactive ingredient listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMylan Institutional LLC
Application holderMYLAN INSTITUTIONAL LLC
FDA applicationNDA017788 (NDA)
Labeler code67457
First marketedApr 1978
Product typeHuman Prescription Drug
Portfolio168 products on file

More NDCs from Mylan Institutional LLC labeler code 67457

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🔒 Drug Abuse and Dependence 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 53 words ▾

INDICATIONS AND USAGE RIMSO-50 ® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50 ® has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.

⏱️ Dosage and Administration 143 words ▾

DOSAGE AND ADMINISTRATION Instillation of 50 mL of RIMSO-50 ® (dimethyl sulfoxide) directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding.

It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately. Administration of oral analgesic medication or suppositories containing belladonna and opium prior to the instillation of RIMSO-50 ® can reduce bladder spasm.

In patients with severe interstitial cystitis with very sensitive bladders, the initial treatment, and possibly the second and third (depending on patient response) should be done under anesthesia. (Saddle block has been suggested).

⛔ Contraindications 3 words ▾

CONTRAINDICATIONS None known.

⚠️ Warnings 57 words ▾

WARNINGS Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide. This hypersensitivity has been reported in one patients receiving intravesical RIMSO-50 ® . The physician should be cognizant of this possibility in prescribing RIMSO-50 ® . If anaphylactoid symptoms develop, appropriate therapy should be instituted.

🤒 Adverse Reactions 75 words ▾

ADVERSE REACTIONS A garlic-like taste may be noted by the patient within a few minutes after instillation of RIMSO-50 ® (dimethyl sulfoxide). This taste may last several hours and because of the presence of metabolites, an odor on the breath and skin may remain for 72 hours. Transient chemical cystitis has been noted following instillation of dimethyl sulfoxide.

The patient may experience moderately severe discomfort on administration. Usually this becomes less prominent with repeated administration.

🆘 Overdosage 63 words ▾

OVERDOSAGE The oral LD 50 of dimethyl sulfoxide in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of RIMSO-50 ® in the patient. In case of accidental oral ingestion, specific measures should be taken to induce emesis. Additional measures which may be considered are gastric lavage, activated charcoal and force diuresis.

🧬 Clinical Pharmacology 107 words ▾

CLINICAL PHARMACOLOGY Dimethyl sulfoxide is metabolised in man by oxidation to dimethyl sulfone or by reduction to dimethyl sulfide. Dimethyl sulfoxide and dimethyl sulfone are excreted in the urine and feces. Dimethyl sulfide is eliminated through the breath and skin and is responsible for the characteristic odor from patients on dimethyl sulfoxide medication.

Dimethyl sulfone can persist in serum for longer than two weeks after a single intravesical instillation. No residual accumulation of dimethyl sulfoxide has occurred in man or lower animals who have received treatment for protracted periods of time. Following topical application, dimethyl sulfoxide is absorbed and generally distributed in the tissues and body fluids.

📦 How Supplied / Storage and Handling 76 words ▾

HOW SUPPLIED Vials contain 50 mL of sterile and non-pyrogenic RIMSO-50 ® (50% w/w dimethyl sulfoxide aqueous solution). Dimethyl sulfoxide is clear and colorless. NDC 67457-177-50 carton containing a 50 mL vial Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from strong light.

For additional information concerning RIMSO-50®, contact Mylan Institutional LLC, Morgantown, WV 26505. Manufactured for: Mylan Institutional LLC Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Institutional Galway, Ireland

📦 Storage and Handling 44 words ▾

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from strong light. For additional information concerning RIMSO-50®, contact Mylan Institutional LLC, Morgantown, WV 26505. Manufactured for: Mylan Institutional LLC Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Institutional Galway, Ireland

📋 Description 99 words ▾

DESCRIPTION RIMSO-50 ® (dimethyl sulfoxide) (DMSO) 50% w/w Aqueous Solution for intravesical instillation. Each mL contains 0.54 gm dimethyl sulfoxide STERILE AND NON-PYROGENIC. Intravesical instillation for the treatment of interstitial cystitis.

NOT FOR INTRAMUSCULAR OR INTRAVENOUS INJECTION. The active component of RIMSO-50 ® is dimethyl sulfoxide which has the empirical formula C 2 H 6 OS, and is structurally represented as: Dimethyl sulfoxide is a clear, colorless and essentially odorless liquid which is miscible with water and most organic solvents. Other physical characteristics include: molecular weight 78.13, melting point 18.3° C, and a specific gravity of 1.096.

Chemical Structure

💬 Information for Patients ~2 min read ▾

INFORMATION FOR PATIENTS (Physician Copy) RIMSO-50 ® is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis. RIMSO-50 ® will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.

Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a RIMSO-50 ® instillation. A garlic-like taste may be noted by the patient within a few minutes after instillation of RIMSO-50 ® (dimethyl sulfoxide).

This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours. Some patients may experience discomfort on administration of the drug.

Usually this becomes less prominent with repeated administration. If you are pregnant or nursing, ask your physician about the advisability of using RIMSO-50 ® . Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods.

Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment. RIMSO-50® (dimethyl sulfoxide) irrigation, USP 1013L102 Mylan Institutional LLC Morgantown, WV 26505 U.S.A. Revised: 3/2021 MI:RIMSIG:R5 RIMSO-50 is a registered trademark of Mylan Teoranta, a Viatris Company.

INFORMATION FOR PATIENTS (Patient Copy) RIMSO-50 ® is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis. RIMSO-50 ® will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.

Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a RIMSO-50 ® instillation. A garlic-like taste may be noted by the patient within a few minutes after instillation of RIMSO-50 ® (dimethyl sulfoxide).

This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours. Some patients may experience discomfort on administration of the drug.

Usually this becomes less prominent with repeated administration. If you are pregnant or nursing, ask your physician about the advisability of using RIMSO-50 ® . Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods.

Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment.

⚠️ Precautions ~1 min read ▾

PRECAUTIONS Changes in the refractive index and lens opacities have been seen in monkeys, dogs and rabbits given high doses of dimethyl sulfoxide chronically. Since lens changes were noted in animals, full eye evaluations, including slit lamp examinations, are recommended prior to and periodically during treatment. Approximately every six months patients receiving dimethyl sulfoxide should have a biochemical screening, particularly liver and renal function tests, and complete blood count.

Intravesical instillation of RIMSO-50 ® may be harmful to patients with urinary tract malignancy because of dimethyl sulfoxide-induced vasodilation. Some data indicate that dimethyl sulfoxide potentiates other concomitantly administered medications. Dimethyl sulfoxide caused teratogenic responses in hamsters, rats and mice when administered intraperitoneally at high doses (2.5 to 12 gm/kg).

Oral or topical doses of dimethyl sulfoxide did not cause problems of reproduction in rats, mice and hamsters. Topical doses (5 gm/kg first two days, then 2.5 gm/kg - last eight days) produced terata in rabbits, but in another study, topical doses of 1.1 gm/kg days 3 through 16 of gestation failed to produce any abnormalities. There are no adequate and well controlled studies in pregnant women.

Dimethyl sulfoxide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dimethyl sulfoxide is administered to a nursing woman.

Safety and effectiveness in children have not been established. Information available to be given to the patient is reprinted at the end of this text.

🔒 Drug Abuse and Dependence 6 words ▾

DRUG ABUSE AND DEPENDENCE None known.

📄 Package Label / Principal Display Panel 105 words ▾

PRINCIPAL DISPLAY PANEL - 50 mL Vial NDC 67457-177-50 50 mL RIMSO-50 ® (dimethyl sulfoxide) irrigation, USP 50 mL (54 gm) 50% w/w Aqueous Solution For Irrigation Only Not for Injection Rx only Vial Sterile. Non-pyrogenic. Contains: 50% w/w dimethyl sulfoxide in water for injection.

Usual Dosage: See accompanying prescribing information. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from strong light. Manufactured for: Mylan Institutional LLC Morgantown, WV 26505 U.S.A.

Manufactured by: Mylan Institutional Galway, Ireland RIMSO-50 is a registered trademark of Mylan Teoranta, a Viatris Company. MI:177:1C:R5 Mylan.com Rimso-50 (dimethyl sulfoxide) irrigation USP, 50 mL Carton Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
578
Units reimbursed last 4 qtrs
30.2K
Gross reimbursed last 4 qtrs
$323K
Avg / prescription
$558.76
Avg / unit
$10.6875
Latest quarter Q1 2026
85Rx
Fee-for-service vs managed care ⓘ
43% FFS 57% MCO
Fee-for-service · 248 Rx Managed care · 330 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 35 units · 0.4 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 800 units · 8.0 per 100k residents MI New York: 6,850 units · 35.0 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 2,050 units · 16.3 per 100k residents IL Indiana: 700 units · 10.2 per 100k residents IN Ohio: no data reported OH Pennsylvania: 700 units · 5.4 per 100k residents PA New Jersey: no data reported NJ Massachusetts: 4,700 units · 67.1 per 100k residents MA California: 225 units · 0.6 per 100k residents CA Utah: no data reported UT Colorado: 2,700 units · 45.9 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 605 units · 13.4 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 4,454 units · 123 per 100k residents CT Rhode Island: no data reported RI Arizona: 5,000 units · 67.3 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 1,400 units · 30.6 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.4123
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Connecticut 123 /100k
2 Arizona 67.3 /100k
3 Massachusetts 67.1 /100k
4 Colorado 45.9 /100k
5 New York 35.0 /100k
6 Louisiana 30.6 /100k
7 Illinois 16.3 /100k
8 Kentucky 13.4 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Rimso-50 — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Rimso-50. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$103.7K
Claims incl. refills
73
Beneficiaries
45
Spend / beneficiary
$2,305.48
Spend / claim
$1,421.19
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Mylan Institutional LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Mylan Institutional LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J1212 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 67457-0163-02 · Mylan 67457-0182-10 · Mylan →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.